Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Nov 2012 Primary endpoint 'Seizure-frequency' has not been met according to a Pfizer media release.
- 16 Nov 2012 Top-line results have been reported in a Pfizer media release.
- 20 Aug 2012 Actual patient number changed from 333 to 334 as reported by ClinicalTrials.gov.